Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis.

Publikation

Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis.

Wissenschaftlicher Artikel/Review - 01.03.2022

Katsanos Aristeidis H, Psychogios Klearchos, Turc Guillaume, Sacco Simona, Maurice De Sousa Dave, De Marchis Gian Marco, Palaiodimou Lina, Filippou Dimitrios K, Ahmed Niaz, Sarraj Amrou, Menon Bijoy K, Tsivgoulis Georgios

Zitation

Katsanos A, Psychogios K, Turc G, Sacco S, Maurice De Sousa D, De Marchis G, Palaiodimou L, Filippou D, Ahmed N, Sarraj A, Menon B, Tsivgoulis G. Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e224506.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

JAMA Netw Open 2022; 5

Veröffentlichungsdatum

01.03.2022

eISSN (Online)

2574-3805

Seiten

e224506

Kurzbeschreibung/Zielsetzung

Tenecteplase is being evaluated as an alternative thrombolytic agent for the treatment of acute ischemic stroke (AIS) within ongoing randomized clinical trials (RCTs). In addition, nonrandomized clinical experiences with off-label use of tenecteplase vs alteplase for AIS treatment are being published.